Riskpilot← Back to searchSign inGet full accessTREATMENT PHARMA ApS
APSActiveCVR 37208035Ove Jensens Alle 35KManufacture of other food products n.e.c. · NACE 1089Est. 20151 employeeswww.apuremind.dk
Revenue 2024
DKK -37K
-17% vs 2023
EBITDA margin
100.0%
+17% vs 2023
Equity ratio
22.8%
Financial strength
Net profit 2024
DKK -38K
+19% vs 2023
| Revenue | DKK -37K | -17% |
| EBITDA | DKK -37K | +17% |
| Net profit | DKK -38K | +19% |
| Total assets | DKK 376K | +435% |
| Equity | DKK 86K | +212% |
| Employees | 1 | — |
Legal name
TREATMENT PHARMA ApS
CVR number
37208035
Legal form
Anpartsselskab
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
5. november 2015
Share capital
DKK 58.824
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af direktøren.
Company purpose
Virksomhedens formål er drive virksomhed med fremstilling og videresalg af naturligt kosttilskud
Address
Ove Jensens Alle 35K
Phone
+4531214282
Email
anne@apuremind.dk
Website
www.apuremind.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -37 | -10 | -7 | -3 | -3 | -3 | -23 | -45 | -37 |
| Staff expenses | -148 | -4 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -185 | -14 | -7 | -3 | -3 | -3 | -23 | -45 | -37 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -185 | -14 | -7 | -3 | -3 | -3 | -23 | -45 | -37 |
| Net financials | -1 | -2 | -2 | -2 | 166 | -0 | -1 | -2 | -1 |
| Profit before tax | -186 | -15 | -9 | -5 | 163 | -3 | -24 | -47 | -38 |
| Tax | -41 | -3 | 44 | -0 | -0 | -1 | -0 | -0 | -0 |
| Net profit | -145 | -12 | -53 | -5 | 163 | -3 | -24 | -47 | -38 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 66 | 46 | 3 | 1 | 2 | 2 | 222 | 70 | 376 |
| Equity | -95 | -107 | -160 | -165 | -3 | -5 | -29 | -76 | 86 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 162 | 154 | 163 | 167 | 5 | 7 | 251 | 146 | 290 |
| Total debt | 162 | 154 | 163 | 167 | 5 | 7 | 251 | 146 | 290 |
EBITDA margin
-3690400.0%
This company
15.8%
Market median
-23357062% vs market
20162024
Equity ratio
22.8%
This company
38.2%
Market median
-40% vs market
20162024
Return on equity
-44.8%
This company
18.4%
Market median
-343% vs market
20162024
Net profit margin
-3829000.0%
This company
8.1%
Market median
-47271705% vs market
20162024
Asset turnover
-0.10×
This company
1.12×
Market median
-109% vs market
20162024
Debt / equity
3.39×
This company
0.62×
Market median
-447% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-11-05 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AS Management | Management | 2024 | — | — |
TR Management | Management | 2015 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Anne Simmenæs Holding ApS | Company | 33.3% | 33.3% | 2025 |
Power the Future ApS | Company | 25.0% | 15.0% | 2024 |
Tove Resen Holding ApS | Company | 25.0% | 25.0% | 2015 |
Batak Holding ApS | Company | 25.0% | 25.0% | 2024 |
ASJS Holding ApS | Company | 25.0% | 25.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Tove Resen Holding ApS
TREATMENT PHARMA ApS Board members of TREATMENT PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Simmenæs | Management | 0 companies |
| Tove Resen | Management | 0 companies |